Market's view on Bioventix
Published on April 2024
- A new Alzheimer’s test by Bioventix has been described as the ‘Holy Grail’ of diagnostic testing, highlighting a strong demand for early-stage detection tools in the face of numerous late-stage drug developments.
- Bioventix’s involvement in bd-tau, a biomarker for brain damage, was noted to be superior to p-tau in UK studies, which is significant as it is associated with adverse outcomes in ischaemic stroke and Alzheimer’s.
- There is a temporary slowdown in the adoption rate for troponin which is a concern amidst a competitive Alzheimer’s environment with in-house monoclonal antibodies being developed.
- The company’s share price has shown a significant rise, and Cavendish has adjusted their price target upwards substantially, which has been positively viewed.
- Concerns were raised about potential movements in the market or company, particularly as substantial quantities of shares seem to be in demand, suggesting a possible strategic positioning by investors.
- Discussions included the importance of strategic share sales by directors, which can potentially enhance share prices by attracting new financial investors who then need to buy additional shares in the open market.